Investor overview
A renewable catalog of today’s viruses
Flip through our investor trifold below for an overview of the opportunity, our products and our business model. Supplementary detail on timing, traction and our roadmap follows.
Why now
Regulators expect current strains
FDA rules for influenza antigen tests (21 CFR 866.3328) require manufacturers to evaluate their tests against newly circulating strains every year.
Demand renews every season
As circulating strains shift, test developers and labs need access ti new strains to ensure testing accuracy
Supply without upfront cost
Partners supply isolates under a royalty model, which helps to reduce upfront production costs.
Traction and roadmap
2026: done
- Biosafety Level 2 laboratory established in Buffalo, NY
- Legally approved material transfer agreement for isolate partners
- Initial isolate agreement with the New York State Department of Health
- FuzeHub Commercialization Competition finalist
2027: planned
- Launch of influenza A and B as first products
- ISO 13485 quality system certification (target)
Next
- RSV and SARS-CoV-2 materials
- Continue to expand CIPN
- ISO 17034 reference material producer accreditation (target)
Coming soon
Investment opportunity
Details on our financing round will be shared here soon. In the meantime, we welcome conversations with investors who share our focus on diagnostics and public health.
Part of New York’s life science community
This page does not constitute an offer to sell or a solicitation of an offer to buy securities. Forward-looking statements and targets are subject to risk and uncertainty.